| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8940714 | ENDO PHARMS INC | Cyanocobalamin low viscosity aqueous formulations for intranasal delivery |
Feb, 2024
(4 months from now) | |
| US7404489 | ENDO PHARMS INC | Cyanocobalamin low viscosity aqueous formulations for intranasal delivery |
Mar, 2024
(5 months from now) | |
| US9415007 | ENDO PHARMS INC | Cyanocobalamin low viscosity aqueous formulations for intranasal delivery |
Jul, 2024
(9 months from now) | |
| US7879349 | ENDO PHARMS INC | Cyanocobalamin low viscosity aqueous formulations for intranasal delivery |
Aug, 2024
(9 months from now) | |
| US8003353 | ENDO PHARMS INC | Cyanocobalamin low viscosity aqueous formulations for intranasal delivery |
Aug, 2024
(9 months from now) | |
| US7229636 | ENDO PHARMS INC | Cyanocobalamin low viscosity aqueous formulations for intranasal delivery |
Aug, 2024
(9 months from now) | |
Nascobal is owned by Endo Pharms Inc.
Nascobal contains Cyanocobalamin.
Nascobal has a total of 6 drug patents out of which 0 drug patents have expired.
Nascobal was authorised for market use on 31 January, 2005.
Nascobal is available in spray, metered;nasal dosage forms.
Nascobal can be used as nasal administration of cyanocobalamin, supplement for vitamin b12 deficiencies, cyanocobalamin administration through nasal infusion.
The generics of Nascobal are possible to be released after 01 August, 2024.
Drugs and Companies using CYANOCOBALAMIN ingredient
Market Authorisation Date: 31 January, 2005
Treatment: Cyanocobalamin administration through nasal infusion; Supplement for vitamin b12 deficiencies; Nasal administration of cyanocobalamin
Dosage: SPRAY, METERED;NASAL
NASCOBAL family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic